Kura Oncology (KURA) Set to Post Earnings on Tuesday

Kura Oncology (NASDAQ:KURA) is expected to post its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect Kura Oncology to post earnings of ($0.8144) per share and revenue of $24.86 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 8:00 AM ET.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.11. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%. The firm had revenue of $20.87 million for the quarter, compared to analyst estimates of $20.16 million. On average, analysts expect Kura Oncology to post ($3.25) EPS for the current fiscal year and ($2.46) EPS for the next fiscal year.

Kura Oncology Trading Up 0.1%

Shares of KURA stock opened at $9.62 on Tuesday. Kura Oncology has a twelve month low of $7.36 and a twelve month high of $13.90. The company has a market capitalization of $855.80 million, a price-to-earnings ratio of -2.85 and a beta of 0.47. The firm has a 50-day moving average price of $11.28 and a 200 day moving average price of $9.79. The company has a current ratio of 4.73, a quick ratio of 4.71 and a debt-to-equity ratio of 0.12.

Wall Street Analysts Forecast Growth

KURA has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a research note on Thursday, October 15th. Barclays set a $24.00 target price on shares of Kura Oncology in a research note on Wednesday, October 14th. UBS Group restated a “buy” rating on shares of Kura Oncology in a report on Monday, October 5th. Raymond James Financial set a $24.00 price target on Kura Oncology in a research note on Monday, August 24th. Finally, Citizens Jmp reissued a “market outperform” rating and issued a $24.00 target price on shares of Kura Oncology in a research report on Monday, August 24th. Eleven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $25.35.

Insider Activity

In other news, insider Mollie Leoni sold 28,802 shares of Kura Oncology stock in a transaction on Tuesday, September 29th. The stock was sold at an average price of $10.75, for a total transaction of $309,621.50. Following the transaction, the insider directly owned 141,095 shares in the company, valued at approximately $1,516,771.25. This trade represents a 16.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Teresa Bair sold 31,487 shares of the business’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $12.63, for a total transaction of $397,680.81. Following the completion of the sale, the insider owned 195,444 shares in the company, valued at approximately $2,468,457.72. This trade represents a 13.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 153,881 shares of company stock worth $1,708,183 in the last quarter. 7.60% of the stock is currently owned by corporate insiders.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company’s research programs target genetic and molecular drivers of malignancies, with the goal of developing therapies for patients with limited treatment options.

Kura’s lead product candidate has been ziftomenib, an oral, selective menin inhibitor being developed for genetically defined forms of acute myeloid leukemia (AML), including AML associated with NPM1 mutations and KMT2A rearrangements.